Table 2.
The anticancer effect of 5-FU/PEG-PBLG nanoparticles
| LoVo cell xenografts | Tca8113 cell xenografts | |||||
| TDT (d) | IR (%) | TV(cm3) | TDT (d) | IR (%) | TV(cm3) | |
| Blank control | 3.0 | 0 | 4.336 ± 0.485 | 3.5 | 0 | 3.888 ± 0.547 |
| PEG-PBLG | 2.9 | 0 | 4.206 ± 0.308* | 3.6 | 0 | 3.944 ± 0.179* |
| 5-FU | 4.08 | 62.2% | 1.637 ± 0.330# | 4.6 | 65.4% | 1.346 ± 0.142# |
| 5-FU/PEG-PBLG | 4.50 | 77.1% | 0.993 ± 0.122#§ | 5.3 | 89.6% | 0.405 ± 0.174#§ |
TDT, tumor doubling time; IR, inhibition rate; TV, tumor volume at day 21 for LoVo cell xenografts and at day 34 for Tca 8113 cell xenografts.
*compared with blank control, p > 0.05.
#compared with blank control, p < 0.01,
§compared with 5-FU, p < 0.01.